EU/3/05/324

Table of contents

About

On 28 October 2005, orphan designation (EU/3/05/324) was granted by the European Commission to ACE Pharmaceuticals BV, The Netherlands, for levamisol hydrochloride for the treatment of nephrotic syndrome.

Key facts

Active substance
Levamisol hydrochloride
Disease / condition
Treatment of nephrotic syndrome
Date of first decision
28/10/2005
Outcome
Positive
EU designation number
EU/3/05/324

Sponsor's contact details

ACE Pharmaceuticals BV
Schepenveld 41
3891 ZK Zeewolde
The Netherlands
Telephone: +31 36 522 72 01
Telefax: +31 36 522 9096
E-mail: ace@ace-pharm.nl

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

How useful was this page?

Add your rating